Navigation Links
Researchers find new hope for treatment of chronic leukemia
Date:8/17/2011

Wednesday, August 17, 2011, Cleveland: While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.

This information was released in the online edition of Blood, a weekly medical journal published by the American Society of Hematology.

Chronic lymphocytic leukemia (CLL), a cancer of the white blood cells that is incurable with standard treatment, is the most common type of leukemia in the Western Hemisphere. Conventional chemotherapy is effective at controlling CLL for many years, but the disease always relapses. CLL is characterized by an uncontrolled cell growth and division due to a defect in a process called programmed cell death, or apoptosis. A group of proteins called the Bcl-2 family is responsible for this defect.

Alex Almasan, Ph.D., a researcher in the Lerner Research Institute (LRI) of Cleveland Clinic in close collaboration with other researchers in both LRI and the Taussig Cancer Institute of Cleveland Clinic collected blood samples from patients with CLL and tested the ability of a new drug to kill the cancerous cells. The drug, Navitoclax, is already in early stage clinical testing for patients with CLL. Navitoclax appears to be effective for some patients, and until this research study, there had been no clear way to predict who will respond to its effects.

In addition, these studies can be informative to the currently ongoing clinical trials with Navitoclax in other hematologic malignancies or solid tumors.

"Follow-up studies on patients that have been treated with Navitoclax, particularly those that are poor responders, could determine whether the Bcl-2 family genes examined in this study may also be important for development of resistance to this agent," said Almasan.


'/>"/>

Contact: Dan Doron
dorond@ccf.org
216-312-0428
Lerner Research Institute
Source:Eurekalert

Page: 1

Related biology news :

1. Researchers find way to align gold nanorods on a large scale
2. UBC researchers discover key mechanism that regulates shape and growth of plants
3. Researchers discover oldest evidence of nails in modern primates
4. Researchers map pathway of infection for a common, potentially life-threatening respiratory virus
5. Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors
6. Researchers discover freshwater mussel species thought to be extinct
7. NYU Langone researchers identify a signaling pathway as possible target for cancer treatment
8. Toronto researchers first to discover new genetic clue in the development of rheumatoid arthritis
9. Researchers decode workings of mysterious, but critical TB drug
10. Researchers fight cholera with computer forecasting
11. Vanderbilt researchers, international team, uncover genes linked to multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... DAVIS--Mosquito traps that reek like latrines may be no ... team led by chemical ecologist Walter Leal has discovered ... making humans hold their noses. The synthetic mixture, ... just as enticing to Culex mosquitoes as the current ...
... and South Africa have created a biophysical methodology ... potentially remedy even substantial hearing loss. The authors ... the ear to recognize frequencies originally associated with ... the open-access journal PLoS Computational Biology . ...
... Presenting new research about national, home and business security ... of Houston professor and his colleagues has become the ... to surveillance. Two professors and two ... Institute of Electrical and Electronics Engineers International Conference on ...
Cached Biology News:No more big stink: scent lures mosquitoes, but humans can't smell it 2Biophysical method may help to recover hearing 2National security remedies among topics at surveillance confab 2National security remedies among topics at surveillance confab 3
(Date:11/21/2014)... (PRWEB) November 20, 2014 The ... public policy research organization representing leading California academic ... and PwC US today released a ... life sciences industry growth. The trend shows a ... 2015 California Biomedical Industry Report indicates ...
(Date:11/21/2014)... 21, 2014 Why did Stephen Hawking ... Einstein so instantly recognizable? Why have they become icons ... and author Hilton Ratcliffe seeks out the answers to ... all to do with science. In " Stephen Hawking ... November 21, 2014), Ratcliffe puts it plainly: , ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
(Date:11/18/2014)... November 17, 2014 RPS Diagnostics ... tests – today announces its third annual partnership ... (CDC) Get Smart About Antibiotics Week from November ... a national campaign designed to highlight the coordinated ... and non-profit and for-profit partners to provide education ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3
... Universite de Montreal and Validapro Biosciences Inc. have signed an ... standards of the biotherapeutic manufacturing unit located at the Faculty ... veterinary clinical use. , ... Laval, ...
... 19 , - Completed ... Opsona Therapeutics, a biotechnology company focused ... diseases, today,announced that Roche Venture Fund and Enterprise Ireland ... financing announced in February,this year, bringing the total round ...
... for Mometasone Furoate/Formoterol Combination for Asthma and ... (NYSE: SGP ) today announced ... for the development and commercialization of fixed-dose ... and chronic obstructive pulmonary disease (COPD). ...
Cached Biology Technology:Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 2Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 2Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 3Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 4Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 5Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 6Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 7Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD 8
...
MultiWash III w/ 12-portStandard Manifold...
...
... Streptavidin Sepharose High Performance, 5 ... media used in HiTrap Streptavidin columns ... compounds.Ideal for packing into Tricorn 5/50 ... when larger scale purifications are required.Extremely ...
Biology Products: